187 related articles for article (PubMed ID: 33211832)
1. MLL-menin and FLT3 inhibitors team up for AML.
Perl AE
Blood; 2020 Nov; 136(21):2369-2370. PubMed ID: 33211832
[No Abstract] [Full Text] [Related]
2. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.
Balgobind BV; Zwaan CM; Pieters R; Van den Heuvel-Eibrink MM
Leukemia; 2011 Aug; 25(8):1239-48. PubMed ID: 21566656
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.
Dicker F; Haferlach C; Sundermann J; Wendland N; Weiss T; Kern W; Haferlach T; Schnittger S
Leukemia; 2010 Aug; 24(8):1528-32. PubMed ID: 20520634
[No Abstract] [Full Text] [Related]
4. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
[TBL] [Abstract][Full Text] [Related]
5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
[TBL] [Abstract][Full Text] [Related]
7. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
8. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.
Shimada A; Taki T; Tabuchi K; Taketani T; Hanada R; Tawa A; Tsuchida M; Horibe K; Tsukimoto I; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):264-9. PubMed ID: 17763464
[TBL] [Abstract][Full Text] [Related]
9. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
10. [FLT3 inhibitors for acute myeloid leukemia].
Kiyoi H
Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
[TBL] [Abstract][Full Text] [Related]
11. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.
Chien W; Sun QY; Ding LW; Mayakonda A; Takao S; Liu L; Lim SL; Tan KT; Garg M; De Sousa Maria Varela A; Xiao J; Jacob N; Behrens K; Stocking C; Lill M; Madan V; Hattori N; Gery S; Ogawa S; Wakita S; Ikezoe T; Shih LY; Alpermann T; Haferlach T; Yang H; Koeffler HP
Leukemia; 2017 Mar; 31(3):762-766. PubMed ID: 27881871
[No Abstract] [Full Text] [Related]
13. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
15. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanisms in the development of acute myeloid leukemia].
Ichikawa M; Kurokawa M
Nihon Rinsho; 2009 Oct; 67(10):1889-93. PubMed ID: 19860185
[TBL] [Abstract][Full Text] [Related]
17. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
18. FLT3
Hyrenius-Wittsten A; Pilheden M; Falqués-Costa A; Eriksson M; Sturesson H; Schneider P; Wander P; Garcia-Ruiz C; Liu J; Ågerstam H; Hultquist A; Lilljebjörn H; Stam RW; Järås M; Hagström-Andersson AK
Leukemia; 2019 Sep; 33(9):2310-2314. PubMed ID: 30953031
[No Abstract] [Full Text] [Related]
19. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
Gaidzik V; Döhner K
Semin Oncol; 2008 Aug; 35(4):346-55. PubMed ID: 18692685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
